Hepatitis C Channel
Topics & Medications
Related Channels


Clinical Effects

Studies have evaluated using PegIntron for hepatitis C. In one study, 41 percent to 75 percent of people using PegIntron with ribavirin had no evidence of hepatitis C (as measured by undetectable virus levels in the blood) 24 months after beginning treatment. Different rates of response were seen with different types of hepatitis C.

When and How to Use It

Some general considerations to keep in mind during treatment with PegIntron include the following:
  • PegIntron comes as an injection that is given subcutaneously (just under the skin) once a week for 24 weeks up to 1 year (depending on various factors).
  • Use the medicine on the same day each week.
  • This medication comes as injection pens or in vials. Either way, each vial or pen is for a single use only. Any unused portion must be discarded; it cannot be saved for later.
  • It is best to inject PegIntron into areas of the skin that have a layer of fat underneath. This includes the thigh, the outer upper arm, or stomach (away from the navel). Try to rotate the injection sites; do not inject in the same place twice in a row.
  • Make sure your healthcare provider teaches you exactly how to inject PegIntron. This includes:


    • How to prepare the skin
    • How to prepare and mix the injection
    • How to inject the medication
    • What to do with your used needles (this may vary, depending on the local laws and regulations).

If you are not comfortable with any part of the process, please let your healthcare provider know.

  • For the medication to work properly, it must be used as prescribed.

PegIntron Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.